| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 61,274 | 74,603 | 58,809 | 78,157 |
| Marketable securities, current | 174,397 | 173,934 | 133,075 | 136,397 |
| Accounts receivable | 2,883 | 2,401 | 6,542 | 2,158 |
| Prepaid expenses and other current assets | 6,817 | 7,172 | 8,438 | 8,017 |
| Total current assets | 245,371 | 258,110 | 206,864 | 224,729 |
| Marketable securities, non-current | 32,600 | 48,563 | 7,875 | 8,419 |
| Property and equipment, net | 4,492 | 4,744 | 5,134 | 5,540 |
| Right-of-use asset | 39,090 | 40,532 | 41,961 | 54,218 |
| Restricted cash | 3,443 | 3,443 | 3,443 | 3,443 |
| Other assets | 3,865 | 3,683 | 211 | 178 |
| Total assets | 328,861 | 359,075 | 265,488 | 296,527 |
| Accounts payable | 773 | 858 | 1,333 | 2,216 |
| Accrued expenses and other current liabilities | 9,830 | 13,314 | 11,270 | 13,554 |
| Deferred revenue, current | 10,124 | 12,493 | 17,126 | 22,620 |
| Operating lease liability, current | 6,522 | 6,367 | 6,216 | 6,066 |
| Total current liabilities | 27,249 | 33,032 | 35,945 | 44,456 |
| Deferred revenue, net of current | 15,440 | 15,841 | 19,888 | 21,150 |
| Operating lease liability, net of current | 51,925 | 53,615 | 55,247 | 56,857 |
| Total liabilities | 94,614 | 102,488 | 111,080 | 122,463 |
| Common stock, par value of 0.0001 per share 300,000,000 shares authorized as of march31, 2026, and december31, 2025, respectively, and 104,036,350 and 96,914,418 shares issued and outstanding as of march31, 2026 and december31, 2025, respectively | 10 | 9 | 7 | 7 |
| Additional paid-in capital | 998,381 | 995,221 | 872,521 | 860,128 |
| Accumulated other comprehensive income | -322 | 50 | 87 | -30 |
| Accumulated deficit | -763,822 | -738,693 | -718,207 | -686,041 |
| Total stockholders equity | 234,247 | 256,587 | 154,408 | 174,064 |
| Total liabilities and stockholders equity | 328,861 | 359,075 | 265,488 | 296,527 |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)